Incidence of cardiovascular events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Pooled data from 3 large randomized clinical trials

被引：0
|
作者：
Bissonnette, Robert [1 ]
Fernandez-Penas, Pablo [2 ,3 ]
Puig, Lluis [4 ]
Mendelsohn, Alan M. [5 ]
Rozzo, Stephen J. [5 ]
Menter, Alan [6 ,7 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[5] 5Sun Pharmaceut Ind Inc, Princeton, NJ USA
[6] Baylor Scott & White, Div Dermatol, Dallas, TX USA
[7] Texas A&M Coll Med, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9796
引用
收藏
页码：AB79 / AB79
页数：1
相关论文
共 50 条
  • [31] Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials
    Blauvelt, A.
    Sofen, H.
    Papp, K.
    Gooderham, M.
    Tyring, S.
    Zhao, Y.
    Lowry, S.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (12) : 2305 - 2312
  • [32] Median time to treatment response in patients with moderate-to-severe plaque psoriasis treated with brodalumab 210 mg or ustekinumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Lebwohl, Mark
    Green, Lawrence
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB167 - AB167
  • [33] Bimekizumab safety and tolerability in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in five phase 3/3b clinical trials
    Gordon, Kenneth B.
    Gooderham, Melinda
    Foley, Peter
    Okubo, Yukari
    Warren, Richard B.
    Peterson, Luke
    Madden, Cynthia
    Szilagyi, Balint
    Deherder, Delphine
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB22 - AB22
  • [34] Long-term safety of tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis through 148 weeks from two phase 3 trials
    Reich, K.
    Thaci, D.
    Pau-Charles, I.
    Igarashi, A.
    Ohtsuki, M.
    Lebwohl, M.
    Cantrell, W.
    Rozzo, S.
    Blauvelt, A.
    Iversen, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 47 - 48
  • [35] Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials
    Menter, A
    Hamilton, T
    Caro, I
    Chen-Rundle, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P156 - P156
  • [36] Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis Analysis of Results From 3 Randomized Phase 3 Clinical Trials
    Armstrong, April W.
    Lynde, Charles W.
    McBride, Sandy R.
    Stahle, Mona
    Edson-Heredia, Emily
    Zhu, Baojin
    Amato, David
    Nikai, Enkeleida
    Yang, Fan Emily
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2016, 152 (06) : 661 - 669
  • [37] Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
    Sandra Adsit
    Enrique Rivas Zaldivar
    Howard Sofen
    Ignacio Dei-Cas
    César Maldonado-García
    Elkin O. Peñaranda
    Luís Puig
    Xiangyi Meng
    Todd Fox
    Adriana Guana
    Advances in Therapy, 2017, 34 : 1327 - 1339
  • [38] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Blauvelt, Andrew
    Tada, Yayoi
    Iversen, Lars
    Mrowietz, Ulrich
    Lebwohl, Mark
    Wang, Maggie
    Vanvoorden, Veerle
    Cullen, Eva
    Staelens, Fabienne
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [39] Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
    Adsit, Sandra
    Rivas Zaldivar, Enrique
    Sofen, Howard
    Dei-Cas, Ignacio
    Maldonado-Garcia, Cesar
    Penaranda, Elkin O.
    Puig, Luis
    Meng, Xiangyi
    Fox, Todd
    Guana, Adriana
    ADVANCES IN THERAPY, 2017, 34 (06) : 1327 - 1339
  • [40] Bimekizumab short-term and longer-term infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials
    Reich, Kristian
    Okubo, Yukari
    Gordon, Kenneth B.
    Blauvelt, Andrew
    Armstrong, April
    De Cuyper, Dirk
    Cioffi, Christopher
    Peterson, Luke
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB146 - AB146
12345